Guerbet's 1999 results show increased profits:
This article was originally published in Clinica
Guerbet, the French imaging group specialising in contrast agents, has announced its full-year results for 1999, including a net profit of FFr9 million ($1.3 million), compared with last year's losses of Fr66.6 million ($9.8 million). Operating profits were up 28% to Fr55.6 million, on a 4.8% rise in turnover to Fr1.2 billion. Michel Guerbet, the group's chairman and managing director, underlined the success of its X-ray and MRI products, Xenetix and Dotarem, which generated overall growth of 33% and 23%, respectively (see Clinica No 883, p 9).
You may also be interested in...
Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.
Grail announced results from an initial validation study that showed its early-detection blood test could identify 12 of the deadliest cancers with a low rate of false-positive results.
Shanghai Henlius Biotech has announced that China’s NMPA has accepted the firm’s filing for its HLX14 denosumab biosimilar. Meanwhile, the company has also announced dosing the first patient in a Phase II clinical trial of its novel HLX10 anti-PD-1 monoclonal antibody.